Publications by authors named "Eman Ahmed El-Attar"

Egypt is the third most densely inhabited African country. Due to the economic burden and healthcare costs of overpopulation, genomic and genetic testing is a huge challenge. However, in the era of precision medicine, Egypt is taking a shift in approach from "one-size-fits all" to more personalized healthcare via advancing the practice of medical genetics and genomics across the country.

View Article and Find Full Text PDF

Background: Anti-Müllerian hormone (AMH) is an important determinant of ovarian reserve in fertility workups in many clinical settings. Thus, we investigated the age dependent decline in AMH specific to the Egyptian population and sought to establish an age dependent reference interval parametrically.

Methods: Serum samples were collected from 841 apparently healthy women.

View Article and Find Full Text PDF

The search for novel non-invasive biomarkers such as epigenetic molecular markers is new hope for common and burdensome cancers. We aim to assess serum expression of miRNA 27a and miRNA150-5p in endometrial cancer patients. Serum was drawn for 36 un-intervened endometrial cancer patients scheduled for hysterectomy and 35 controls.

View Article and Find Full Text PDF

Synopsis of recent research by authors named "Eman Ahmed El-Attar"

  • - Eman Ahmed El-Attar's recent research primarily focuses on the implications of genomics and personalized medicine in Egypt, addressing both the challenges posed by overpopulation and the shift towards individualized healthcare strategies in the context of medical genetics.
  • - The author developed a nomogram for age-specific anti-Müllerian hormone (AMH) levels to establish reference intervals for ovarian reserve in healthy Egyptian females, highlighting the importance of AMH in fertility treatments and assessments.
  • - El-Attar also explores non-invasive biomarkers for endometrial carcinoma through the evaluation of circulating microRNAs, aiming to establish their potential utility in cancer diagnostics and the development of targeted therapies.